comparemela.com
Home
Live Updates
FDA Approves Benralizumab to Treat Pediatric Patients Aged 6
FDA Approves Benralizumab to Treat Pediatric Patients Aged 6
FDA Approves Benralizumab to Treat Pediatric Patients Aged 6 to 11 Years With Severe Asthma
Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.
Related Keywords
Liz Bodin ,
Lynda Mitchell ,
Olga Miltsova ,
Allergy Asthma Network ,
Astrazeneca ,
Asthma Network ,
Long Term Safety Study ,
Children With Severe Eosinophilic Asthma ,